United States, 09 Feb, 2026 — MDSAP The Medical Device Single Audit Program (MDSAP) remains the most efficient pathway for medical device manufacturers to satisfy the Quality Management System (QMS) requirements of multiple regulatory jurisdictions through a single, comprehensive audit. As of February 2, 2026, the program has reached a critical milestone with the full implementation of the U.S. FDA’s Quality Management System Regulation (QMSR), which formally harmonizes U.S. requirements with the international ISO 13485:2016 standard.
MEDICAL DEVICE GUIDANCE IMPORTS NAVIGATING THE DUAL-PORTAL SYSTEM
Participating in MDSAP offers medical device organizations several strategic and operational advantages:
- Single Audit for Multiple Markets: One audit satisfies the regulatory requirements of all five founding members: the USA (FDA), Canada (Health Canada), Australia (TGA), Brazil (ANVISA), and Japan (MHLW/PMDA).
- Reduced Audit Fatigue: Manufacturers avoid redundant, back-to-back inspections from different national authorities, minimizing disruption to daily operations.
- Faster Global Market Access: Compliance with the MDSAP model allows simultaneous entry into high-value markets, accelerating the clinical application of new technologies.
- Predictable Audit Scheduling: Routine MDSAP audits are announced and scheduled in advance with a recognized Auditing Organization (AO), unlike traditional unannounced FDA inspections.
- Enhanced Resource Allocation: By streamlining compliance into one sequence, companies can focus more on innovation and product improvement rather than managing multiple sets of documentation.
THE MEDICAL DEVICE SINGLE AUDIT PROGRAM AUDIT CYCLE AND STRUCTURE
The program operates on a three-year cycle designed to ensure continuous compliance and patient safety.
The Three-Year Audit Cycle:
- Year 1: Initial Certification Audit: Divided into Stage 1 (Documentation and Preparedness Review) and Stage 2 (On-site implementation and compliance evaluation).
- Year 2: Surveillance Audit: A yearly check-in to assess any significant changes to the QMS or product lines.
- Year 3: Surveillance Audit: A second annual check to maintain the certificate.
- End of Year 3: Recertification Audit: A complete re-evaluation to begin the next three-year cycle.
The 7 Process-Based Core Elements:
Auditors use a structured, process-based approach to evaluate these seven critical elements:
- Management: Evaluates top management’s role in planning and supporting the QMS.
- Measurement, Analysis, and Improvement: Focuses on the “CAPA engine” and identification of systemic issues.
- Design and Development: Ensures products are developed under strict controls and meet user needs.
- Production and Service Controls: Confirms manufacturing processes are reliable and validated.
- Purchasing: Verifies oversight of suppliers and outsourced services.
- Device Marketing Authorization & Facility Registration: Ensures all required clearances are obtained before distribution.
- Adverse Events & Advisory Notices Reporting: Evaluates the transparency and speed of mandatory regulatory reporting.
MEDICAL DEVICE SINGLE AUDIT PROGRAM CRITICAL UPDATES FOR 2026
The 2026 update introduces several vital changes that impact manufacturer readiness:
- FDA QMSR Alignment: With the QMSR now in effect, U.S. compliance is almost entirely anchored in ISO 13485:2016. Organizations previously only compliant with 21 CFR Part 820 must close gaps in areas like lifecycle risk management and personnel competency.
- AI and PCCP Integration: New guidance on Predetermined Change Control Plans (PCCP) allows AI-enabled devices to evolve without requiring new marketing submissions for every iteration, provided they stay within pre-approved boundaries.
- Rigorous Recordkeeping: There is an increased focus on the Medical Device Technical File, which must be maintained as a “living document” throughout the device lifecycle, incorporating new post-market data and risk assessments.